Literature DB >> 25939291

Familial hypercholesterolemia.

Victoria Enchia Bouhairie1, Anne Carol Goldberg2.   

Abstract

Familial hypercholesterolemia is a common, inherited disorder of cholesterol metabolism that leads to early cardiovascular morbidity and mortality. It is underdiagnosed and undertreated. Statins, ezetimibe, bile acid sequestrants, niacin, lomitapide, mipomersen, and low-density lipoprotein (LDL) apheresis are treatments that can lower LDL cholesterol levels. Early treatment can lead to substantial reduction of cardiovascular events and death in patients with familial hypercholesterolemia. It is important to increase awareness of this disorder in physicians and patients to reduce the burden of this disorder.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bile acid sequestrants; Ezetimibe; Familial hypercholesterolemia; LDL apheresis; Lomitapide; Mipomersen; Statins

Mesh:

Substances:

Year:  2015        PMID: 25939291      PMCID: PMC4472364          DOI: 10.1016/j.ccl.2015.01.001

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  52 in total

1.  Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation's leading killer.

Authors:  James S Forrester
Journal:  J Am Coll Cardiol       Date:  2010-08-17       Impact factor: 24.094

2.  Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Authors:  Evan A Stein; Scott Mellis; George D Yancopoulos; Neil Stahl; Douglas Logan; William B Smith; Eleanor Lisbon; Maria Gutierrez; Cheryle Webb; Richard Wu; Yunling Du; Therese Kranz; Evelyn Gasparino; Gary D Swergold
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

Review 3.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

4.  Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

Authors:  Evan A Stein; Dan Gipe; Jean Bergeron; Daniel Gaudet; Robert Weiss; Robert Dufour; Richard Wu; Robert Pordy
Journal:  Lancet       Date:  2012-05-26       Impact factor: 79.321

Review 5.  LDL apheresis.

Authors:  Gilbert R Thompson
Journal:  Atherosclerosis       Date:  2003-03       Impact factor: 5.162

6.  Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.

Authors:  Albert Wiegman; Barbara A Hutten; Eric de Groot; Jessica Rodenburg; Henk D Bakker; Harry R Büller; Eric J G Sijbrands; John J P Kastelein
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

7.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors:  Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal:  Lancet       Date:  2012-11-02       Impact factor: 79.321

Review 8.  Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.

Authors:  William Insull
Journal:  South Med J       Date:  2006-03       Impact factor: 0.954

9.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

Review 10.  Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Authors:  Marianne Abifadel; Sandy Elbitar; Petra El Khoury; Youmna Ghaleb; Mélody Chémaly; Marie-Line Moussalli; Jean-Pierre Rabès; Mathilde Varret; Catherine Boileau
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.967

View more
  17 in total

Review 1.  Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.

Authors:  Ricardo Stein; Filipe Ferrari; Fernando Scolari
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 2.  Role of LOX-1 (Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1) as a Cardiovascular Risk Predictor: Mechanistic Insight and Potential Clinical Use.

Authors:  Joaquim Barreto; Sotirios K Karathanasis; Alan Remaley; Andrei C Sposito
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-11-12       Impact factor: 10.514

3.  Xanthogranulomatosis of the spleen: a case report.

Authors:  Goshi Fujimoto; Ken Hayashi; Shigetoshi Yamada; Hiroshi Kusanagi; Koichi Honma
Journal:  Surg Case Rep       Date:  2018-04-19

Review 4.  Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management.

Authors:  Maria Mytilinaiou; Ioannis Kyrou; Mike Khan; Dimitris K Grammatopoulos; Harpal S Randeva
Journal:  Front Pharmacol       Date:  2018-07-12       Impact factor: 5.810

5.  Maternal dyslipidemia and risk for preterm birth.

Authors:  Caitlin J Smith; Rebecca J Baer; Scott P Oltman; Patrick J Breheny; Wei Bao; Jennifer G Robinson; John M Dagle; Liang Liang; Sky K Feuer; Christina D Chambers; Laura L Jelliffe-Pawlowski; Kelli K Ryckman
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

6.  Ketogenic diets, not for everyone.

Authors:  Ira J Goldberg; Nouran Ibrahim; Cindy Bredefeld; Sandra Foo; Vivien Lim; Deborah Gutman; Lesley-Ann Huggins; Robert A Hegele
Journal:  J Clin Lipidol       Date:  2020-10-31       Impact factor: 4.766

7.  Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen.

Authors:  Zuhier Ahmed Awan; Omran M Rashidi; Bandar Ali Al-Shehri; Kaiser Jamil; Ramu Elango; Jumana Y Al-Aama; Robert A Hegele; Babajan Banaganapalli; Noor A Shaik
Journal:  Front Med (Lausanne)       Date:  2021-06-25

8.  Statin Treatments And Dosages In Children With Familial Hypercholesterolemia: Meta-Analysis.

Authors:  Graciane Radaelli; Grasiele Sausen; Claudia Ciceri Cesa; Francisco de Souza Santos; Vera Lucia Portal; Jeruza Lavanholi Neyeloff; Lucia Campos Pellanda
Journal:  Arq Bras Cardiol       Date:  2018-10-18       Impact factor: 2.000

9.  American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines.

Authors:  Paul S Jellinger
Journal:  Diabetes Spectr       Date:  2018-08

10.  Investigation of the underlying genes and mechanism of familial hypercholesterolemia through bioinformatics analysis.

Authors:  Dinghui Wang; Bin Liu; Tianhua Xiong; Wenlong Yu; Qiang She
Journal:  BMC Cardiovasc Disord       Date:  2020-09-16       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.